COMMUNIQUÉS West-GlobeNewswire

BPGbio Sponsors MitoAction Energy Walk at Boston’s Franklin Park Zoo on September 27th, 2025
24/09/2025
Company honored in its commitment to patients and families living with mitochondrial disease; invites the community to walk with BPGbio colleagues and MitoAction BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- BPGbio , Inc [...]
Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research
24/09/2025
Engagement Will Expand Daré’s Engagement in Advancing Women’s Health Innovation and Provide Insights into One of the Most Significant Unmet Needs in Maternal Care SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Daré [...]
Aging in Place, Limited Access to Medical Care and Economic Insecurity Threaten U.S. Senior Health
24/09/2025
New Alignment Health study shows nearly 2 in 5 seniors who experience loneliness say it’s impacting their health, 1 in 4 who have medical debt owe debt equal to 4+ months of living expenses ORANGE, Calif., Sept. 24, [...]
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
24/09/2025
NAARDEN, The Netherlands and MIAMI, Sept. 24, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
Kura Oncology to Participate in Upcoming Investor Conference
24/09/2025
SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
24/09/2025
TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]
Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program
24/09/2025
Program to Provide Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is November 3 rd , 2025 SOUTH SAN FRANCISCO, Calif., Sept. 24, [...]
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
24/09/2025
~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~ ~ Additional $100 million available subject to regulatory and financial milestones ~ ~ Additional $25 million available subject [...]
Healthcare as the World’s Most Strategic Investment: KFSHRC CEO Calls for Global Collaboration at C3 Japan Summit
24/09/2025
TOKYO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Healthcare must be recognized as the world’s most strategic investment in security, prosperity, and resilience—not as a financial burden—declared H.E. Dr. Majid Alfayyadh, [...]
Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando
24/09/2025
IMDX to host symposium on Wednesday, September 24 th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meeting Presenting on GraftAssureIQ at [...]
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease
24/09/2025
~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external control ~ ~ High-dose [...]
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
24/09/2025
FG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor signaling inhibitor (ASRI) and pre-chemotherapy setting FG-3180 to [...]
Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza
24/09/2025
- Update based on FDA End-of- Phase 2 meeting outcome - Phase 3 study start accelerated by six months, in time for the fall 2025 Northern Hemisphere flu season - A single Phase 3 trial of CD388, if successful, may be [...]
LUKE Calls for National Partnerships to Help America’s Heroes Flourish
24/09/2025
NASHVILLE, Tenn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- As the American Association of Christian Counselors (AACC) World Conference in Nashville opens, LUKE Holdings, Inc. (“LUKE”), a trusted leader in healthcare staffing [...]
Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week
24/09/2025
SAN MATEO, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and [...]
Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies
24/09/2025
Clinically significant angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than [...]
Artios Receives U.S. FDA Fast Track Designation for alnodesertib in ATM-negative Metastatic Colorectal Cancer (mCRC)
24/09/2025
U.S. Fast Track designation underscores the strength of the alnodesertib clinical data generated to date and the high degree of unmet need in 3L mCRC CAMBRIDGE, United Kingdom and NEW YORK, September 24, 2025 – Artios [...]
ITM and TerThera Sign Supply Agreement for Medical Radioisotope Terbium-161
24/09/2025
Garching / Munich, Germany, and Breda, the Netherlands, September 24, 2025 – ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, and TerThera BV , a leading provider of GMP-grade [...]
CARBIOS presents its 2025 half-year results and confirms its objective to build a PET biorecycling plant, with a revised timeline.
24/09/2025
CARBIOS has reduced its operating expenses and has a strong cash position of €72 million as of June 30, 2025, providing a cash horizon of more than 12 months The Longlaville plant construction project is now supported [...]

Pages